Stay updated with breaking news from Ropes Gray. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D) Paris and Red Bank, N.J. March 13, 2023
Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes Paris and Red Bank, N.J. March 13, 2023 Sanofi and... | March 13, 2023
Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, ...
Expanding its diabetes expertise, Sanofi will acquire Provention Bio for $25 per share, representing equity value of $2.9 billion.
Sanofi will get a new medicine to complement its older diabetes therapies based on insulin.